Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity.  We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers. 

Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.


Immunotherapies in CIO

CIO News

£1.7 million for vaccine to prevent lung cancer

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.